Xcite®: An Optimized Transient Transfection Platform To Accelerate Your AAV Program From Gene To GMP

By Suparna Sanyal, Director of Commercial Development, CGT Viral Vector, and Peng Wang, Associate Director, Business Development

Advancing an Adeno-Associated Virus (AAV) gene therapy program from the gene bench to Good Manufacturing Practice (GMP) standards requires overcoming critical challenges like inconsistent yields, intricate technology transfer processes, and poor scalability. A streamlined, proprietary transient transfection platform is engineered to address these limitations by integrating an optimized clonal suspension cell line, efficient plasmid design, and a refined production workflow.

This unified, serotype-agnostic approach delivers a robust manufacturing foundation built for speed and quality. The methodology demonstrates the capability to generate substantially higher viral titers—up to 9 times more than conventional systems—along with high-quality full capsid ratios. With process validation from shake flask to 250L bioreactors, development teams can navigate the complex regulatory landscape with increased confidence. Learn how to accelerate your AAV timeline to as little as 12 months from gene to GMP.